Inlyta 5mg Tablet

Kidney cancer

The majority of adverse effects go away as your body becomes used to the medication and don't need to be treated. If they continue or you're concerned about them, speak with your doctor. Nausea
Vomiting
Weight loss
Diarrhea
Loss of appetite
Taste change
Constipation
Tiredness
Weakness
Cough
Joint or muscle pain
Stomach pain
Sore mouth
Redness on hands or feet
Heartburn
Headache

​Inlyta 5mg tablet comes in tablet form and is usually taken with or without food twice a day or as the doctor prescribes. For better results, take Axitinib same time every 12 hours. You should not cut, chew, or break the tablet; swallow the whole tablet with water. If the patient vomits after taking a tablet, do not give another; take the tablet as per the schedule. If the patient feels uncomfortable after starting treatment, inform the doctor immediately.

The anti-cancer drug Inlyta 5mg Tablet functions by preventing the abnormal protein that causes cancer cells to proliferate from doing its job. This aids in halting or delaying the growth of cancerous cells. Tyrosine kinase inhibitors include axitinib. It targets receptor tyrosine kinases, a class of proteins essential for cell signaling, and stops the development of blood vessels inside cancer cells. It helps to control the disease by successfully stopping the growth and spread of cancer cells by interfering with these processes.

​In case you missed any dose consult your doctor. Do not take twice the dose to catch up on the missed dose. This will cause severe side effects and impact your overall health.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Fox, E., Maris, J. M., Widemann, B. C., Goodspeed, W., Goodwin, A., Kromplewski, M., & Blaney, S. M. (2018).  A phase 1 study of axitinib in pediatric patients with refractory solid tumors: A Children’s Oncology Group study (ADVL1215). Clinical Cancer Research, 24(14), 3534–3541.

Fu, L., Liu, Q., Han, Z., Wu, Y., & Jiang, Y. (2023).  Axitinib for hepatocellular carcinoma: Mechanisms and emerging immunotherapy combination strategies. Frontiers in Immunology, 14, 1163967.

Jeong, I. G., Park, J., Ahn, H. K., Park, S. H., Song, C., Hong, B., & Lee, J. L. (2024). Real-world use of axitinib as a second-line therapy in patients with metastatic renal cell carcinoma: A Korean multicenter phase IV study. Investigational and Clinical Urology, 65(2), 136–144.

Powell, S. F., Choueiri, T. K., Motzer, R. J., Escudier, B., Grunwald, V., Donskov, F., & Rini, B. I. (2023). Final overall survival and biomarker analysis of avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (JAVELIN Renal 101). European Urology, 84(3), 320–329.

Teoh, J. Y. C., Leung, C. H., Chan, C. M., Poon, D. M. C., & Ng, C. F. (2024). Systematic review of axitinib for advanced renal cell carcinoma: Real-world evidence and future directions. Cancers, 16(7), 1605

Voss, M. H., Keegan, M. E., Clark, J. W., Halabi, S., McKay, R. R., Atkins, M. B., & Pal, S. K. (2023). Management of adverse events associated with axitinib plus immune checkpoint inhibitor combinations: A real-world multicenter analysis. Targeted Oncology, 18(3), 319–329.